In this study we will investigate the progression of IF/TA in protocol biopsies in a cohort of renal transplants, with a steroid sparing TAC-based immunosuppressive regimen in combination with either sirolimus (SRL) or mycophenolate mofetil (MMF),…
ID
Bron
Aandoening
renal transplantation niertransplantatie
protocol biopsy protocollaire biopsy
Immunosuppression immunosuppressie
IF/TA interstitiele fibrose, tubulesatrofie
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Progression in IF/TA (Chamge in IF/TA between implantation and at month 12.
Achtergrond van het onderzoek
In this study we will investigate the progression of IF/TA in protocol biopsies in a cohort of renal transplants, with a steroid sparing TAC-based immunosuppressive regimen in combination with either sirolimus (SRL) or mycophenolate mofetil (MMF), during the first year after renal transplantation. Furthermore we will investigate if the progression of IF/TA is correlated with donor -, recipient -, and transplant factors, to give insight in potential modifiable and non-modifiable factors associated with this progression.
Doel van het onderzoek
In this study we will investigate the progression of IF/TA in protocol biopsies in a cohort of renal transplants, with a steroid sparing TAC-based immunosuppressive regimen in combination with either sirolimus (SRL) or mycophenolate mofetil (MMF), during the first year after renal transplantation. Furthermore we will investigate if the progression of IF/TA is correlated with donor -, recipient -, and transplant factors, to give insight in potential modifiable and non-modifiable factors associated with this progression.
Onderzoeksopzet
1. At implantation of donor kidney;
2. At month 12 after transplantation.
Onderzoeksproduct en/of interventie
N/A
Algemeen / deelnemers
Wetenschappers
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Patients transplanted between 2003 and February 2008;
2. An adequate T0 and T12 biopsy;
3. Tacrolimus-based regimen with either SRL or MMF;
4. Age between 18 and 80 years.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Other immunosuppressive regimen than tacrolimus, either SRL or MMF;
2. Patients with missing biopsies.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL2350 |
| NTR-old | NTR2456 |
| Ander register | METC MUMC : 10-4-008 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |